Thompson Siegel & Walmsley LLC Acquires 59,685 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Siegel & Walmsley LLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 781,215 shares of the specialty pharmaceutical company's stock after acquiring an additional 59,685 shares during the period. Jazz Pharmaceuticals comprises about 1.3% of Thompson Siegel & Walmsley LLC's holdings, making the stock its 14th largest holding. Thompson Siegel & Walmsley LLC owned approximately 1.27% of Jazz Pharmaceuticals worth $87,035,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Versant Capital Management Inc raised its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock worth $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $33,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on JAZZ. StockNews.com upgraded Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research note on Monday, August 19th. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $175.33.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $5.86 during midday trading on Thursday, reaching $125.10. 757,373 shares of the company's stock were exchanged, compared to its average volume of 678,467. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company's 50 day simple moving average is $112.92 and its two-hundred day simple moving average is $110.52. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The firm has a market capitalization of $7.56 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.